MONDAY, April 11, 2022 (HealthDay News) -- Prostate biopsy and prostate cancer (PC) diagnosis rates decreased during the COVID-19 pandemic among U.S. veterans, according to a study published online April 7 in JAMA Oncology.
Zachary Klaassen, M.D., from Augusta University in Georgia, and colleagues examined the impact of the pandemic on prostate biopsy and PC diagnosis rates among Black and White patients in the Veterans Affairs Health Care System (VAHCS). The analysis included all prostate biopsies performed on patients in the VAHCS without a preexisting PC diagnosis between January 2018 and March 2021.
The researchers found that prior to the pandemic, monthly biopsy numbers ranged between 1,230 and 1,695, of which 56 to 60 percent of results were positive for PC. Between March 2020 and March 2021, the estimated number of missed PC diagnoses ranged from 97 cases (October 2020: 752 cases expected and 655 cases observed) to 573 cases (April 2020: 794 cases expected and 221 cases observed). Biopsy rates were statistically significantly higher among Black versus White men prior to the pandemic (incidence rate ratio, 2.25), and there was no change in biopsy rates associated with race either at the onset of the pandemic or during the recovery period from March 2020 to March 2021. Similar trends were seen for PC diagnosis rates.
"With COVID-19 variant strains, it is possible that continued ongoing delays in PC screening may occur," the authors write.
- Orteronel Misses Goal in Metastatic Hormone-Sensitive Prostate Cancer - Consumer Health News | HealthDay ›
- Obesity Raises a Man's Odds for Fatal Prostate Cancer - Consumer Health News | HealthDay ›
- La obesidad aumenta el riesgo de un hombre de sufrir un cáncer de próstata letal - Consumer Health News | HealthDay ›